project id: TCGA-ESCA; case submitter id: TCGA-S8-A6BV; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.87; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.45; rna integrity number: 7.0; age at index: 76; days to birth: -28111; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1936; age at diagnosis: 28111; ajcc clinical m: MX; ajcc clinical n: N0; ajcc clinical stage: Stage IB; ajcc clinical t: T2; ajcc pathologic m: MX; ajcc pathologic n: N1; ajcc pathologic stage: Stage IIIA; ajcc pathologic t: T3; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 609.0; icd 10 code: C15.5; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Lower third of esophagus; synchronous malignancy: No; tissue or organ of origin: Lower third of esophagus; tumor grade: Not Reported; year of diagnosis: 2012; alcohol history: Yes; is ffpe: false; composition: Not Reported; days to collection: 261; days to sample procurement: 0; initial weight: 180.0; portion submitter id: TCGA-S8-A6BV-01A-21; percent lymphocyte infiltration: 8.0; percent monocyte infiltration: 2.0; percent necrosis: 5.0; percent neutrophil infiltration: 2.0; percent normal cells: 0.0; percent stromal cells: 60.0; percent tumor cells: 35.0; percent tumor nuclei: 75.0;